Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna voice prosthesis coverage & prior auth | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0560

    Voice Prosthesis for Voice Rehabilitation Following Total Laryngectomy

    Customize your policy alerts

    Sign up for Aetna Policy 0560 alerts

    Get alerted when Policy 0560 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, replacement, and coding for indwelling and non-indwelling tracheo-esophageal (TE) voice prostheses and handheld artificial larynx devices for voice rehabilitation after total laryngectomy for Aetna members.

    Policy Summary
    PayerAetna
    PolicyVoice Prosthesis for Voice Rehabilitation Following Total Laryngectomy
    Policy CodePolicy 0560
    Change TypeNo material change
    Effective DateAug 17, 2001
    Last ReviewJul 27, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document recommendation by a laryngologist or speech-language pathologist and confirm selection criteria (adequate pulmonary function and manual dexterity) for prior authorization and medical necessity.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3-6 motypical device life
    80-90%short-term success
    61 daysmedian device life (cohort)
    56%indwelling proportion
    2selection criteria listed

    Coverage and Medical Necessity Criteria

    Medical Necessity Criteria

    Covered when ALL of the following are met

    Indwelling TE prosthesis - initial: Recommended by a laryngologist or a speech-language pathologist for voice rehabilitation following total laryngectomy

    See Appendix for selection criteria

    Indwelling TE prosthesis - replacement: Replacement of indwelling tracheo-esophageal (TE) voice prosthesis when clinically indicated; replacement every 3 to 6 months is considered medically necessary consistent with device lifespan3-6 months

    Replacement is usually carried out as an outpatient procedure

    Non-indwelling prosthesis: Non-indwelling voice prostheses (e.g., Provox NiD) are medically necessary when recommended by a laryngologist or a speech-language pathologist for voice rehabilitation following total laryngectomy

    See Appendix for selection criteria

    Hand-held artificial larynx devices (e.g., Nu Vois, OptiVox, Servox, SolaTone, TruTone, UltraVoice) are considered medically necessary

    Experimental / Investigational

    Not covered / experimental

    Experimental devices: Pneumatic Bionic Voice Prostheses and use of a TE voice prosthesis insufflator are considered experimental and investigational because their clinical value has not been established

    These items are listed as experimental/investigational in the policy

    Selection criteria (indwelling or non-indwelling TE voice prosthesis)

    Covered when ALL of the following are met

    Selection criteria for TE voice prosthesis: Member has adequate pulmonary function to force air from the trachea through the prosthesis into the esophagus; and Member has the manual dexterity to care for the voice prosthesis daily.

    These two criteria are the Appendix selection criteria for indwelling or non-indwelling TE voice prosthesis

    The policy lists Pneumatic Bionic Voice Prostheses and the use of a TE voice prosthesis insufflator as experimental and investigational and therefore excluded from coverage because their clinical value has not been established.

    Prophylactic replacement of a voice prosthesis is not considered feasible or appropriate. A retrospective study found marked inter- and intra-patient variability in device lifetime; prophylactic replacement to prevent 70% of leakages would require a median of 9.4 VPs per year (replacement every ~38 days), and simulation showed that preventing 70% of leakages is generally impossible. The authors concluded prophylactic replacement is not feasible due to the high coefficient of variation in device lifetime.

    Patients considered for a TE voice prosthesis must be able to manage daily device care and have sufficient respiratory function. Specifically, patients need adequate manual dexterity to clean the prosthesis 2–3 times daily and adequate pulmonary function to force air from the trachea through the prosthesis into the esophagus. Individuals with severe upper-extremity impairment (for example, severe rheumatoid arthritis, amputations, or deformities) or those with severe pulmonary disease and/or repeated pneumonitis are poor candidates for TE voice prostheses under accepted guidelines.

    Billing and Coding

    Covered CPT CodesCPTCovered
    31611Construction of tracheoesophageal fistula and subsequent insertion of an alaryngeal speech prosthesis (e.g., voice button, Blom-Singer prosthesis)
    31360-31365Laryngectomy, total
    Covered HCPCS CodesHCPCSCovered
    L8500Artificial larynx, any type
    L8501Tracheostomy speaking valve
    L8505Artificial larynx replacement battery/accessory, any type
    L8507Tracheo-esophageal voice prosthesis, patient inserted, any type, each [e.g., the Provox NiD]
    L8509Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type
    L8511Insert for indwelling tracheoesophageal prosthesis, with or without valve, replacement only, each
    L8512Gelatin capsules or equivalent, for use with tracheoesophageal voice prosthesis, replacement only, per 10
    L8513Cleaning device used with tracheoesophageal voice prosthesis, pipet, brush, or equal, replacement only, each
    L8514Tracheoesophageal puncture dilator, replacement only, each
    L8515Gelatin capsule, application device for use with tracheoesophageal voice prosthesis, each
    No specific code / experimentalmixedExperimental
    Pneumatic Bionic Voice ProsthesesNo specific code
    Tracheoesophageal voice prosthesis insufflatorNo specific code
    Covered ICD-10 CodesICD-10Covered
    C32.0-C32.9Malignant neoplasm of larynx
    D02.0Carcinoma in situ of larynx
    D14.1Benign neoplasm of larynx
    Z85.21Personal history of malignant neoplasm of larynx
    Z90.02Acquired absence of larynx

    Provider Requirements and Operational Guidance

    Prior Authorization

    Codes covered only if selection criteria met; prior auth as required

    Certain CPT, HCPCS and ICD-10 codes listed in this policy are covered only when the policy’s selection criteria are met; obtain prior authorization as required by the payer for procedures and prosthesis insertion/replacement using these codes.

    • Covered CPT codes include 31611 and 31360-31365 when selection criteria are met.
    • Covered HCPCS include L8500, L8501, L8505, L8507, L8509, L8511–L8515 when selection criteria are met.
    • Covered ICD-10 codes include C32.0–C32.9, D02.0, D14.1, Z85.21, Z90.02 when selection criteria are met.
    Prior Authorization

    PA must document pulmonary function and manual dexterity

    Prior authorization documentation should confirm the member meets the policy’s selection criteria by demonstrating adequate pulmonary function to force air through the prosthesis and sufficient manual dexterity to care for the device daily.

    • Document pulmonary function sufficient to force air from the trachea through the prosthesis into the esophagus.

    Clinical Background and Rationale

    Tracheo-esophageal (TE) voice prostheses restore speech after total laryngectomy by shunting exhaled air through a one-way valve into the esophagus to produce TE speech. Devices are available as indwelling prostheses, which are secured with flanges and typically replaced by a clinician every few months, and as non-indwelling (patient-inserted) prostheses. Candidacy requires adequate manual dexterity, sufficient pulmonary function, and patient motivation. Leakage of saliva or reflux through or around the prosthesis and increased airflow resistance are the primary indications for inspection and replacement; the general device life is reported as 3–6 months, although durability varies with diet and adherence to daily maintenance.

    Definitions and Device Variants

    inv-24: Indwelling TE voice prosthesis — definition and typical replacement by clinician
    DefinitionA tracheo-esophageal (TE) voice prosthesis secured with flanges or semi-permanent fixation that is intended to remain in place and typically replaced by a clinician.
    Typical replacement intervalMedically necessary replacement every 3 to 6 months is consistent with the documented life span of most indwelling TE prostheses.
    Examples available in the U.S.Blom-Singer Indwelling Low-Pressure Voice Prosthesis; Provox 2; VoiceMaster.
    Usual setting for replacementReplacement is usually carried out as an outpatient procedure by a physician or speech-language pathologist.
    inv-25: Non-indwelling (patient-inserted) TE voice prosthesis — definition (e.g., Provox NiD) and comment on device life
    Definition
    Policy Summary
    PayerAetna
    PolicyVoice Prosthesis for Voice Rehabilitation Following Total Laryngectomy
    Policy CodePolicy 0560
    Change TypeNo material change
    Effective DateAug 17, 2001
    Last ReviewJul 27, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document recommendation by a laryngologist or speech-language pathologist and confirm selection criteria (adequate pulmonary function and manual dexterity) for prior authorization and medical necessity.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and CodingProvider Requirements and Operational GuidanceClinical Background and RationaleDefinitions and Device Variants
  1. Document manual dexterity to clean and care for the prosthesis 2–3 times daily.
  2. Note

    Check policy history and CPB for prior authorization requirements

    Refer to the policy history and the Clinical Policy Bulletin (CPB) notes for any payer-specific prior authorization requirements or administrative details related to authorization.

    • See Policy History (last review 07/27/2023; next review 06/13/2024) for administrative updates.
    • See Clinical Policy Bulletin Notes for additional administrative information.
    Note

    Recognize indwelling and non-indwelling devices as medically necessary when recommended

    The policy recognizes both indwelling and non-indwelling TE voice prostheses as medically necessary when recommended by a laryngologist or speech-language pathologist; device choice may be based on prior device performance and device life evidence.

    • Indwelling devices (e.g., Blom-Singer, Provox 2) are covered when recommended.
    • Non-indwelling devices (e.g., Provox NiD) are covered when recommended and may be chosen based on durability or patient preference.
    Step Therapy

    No explicit step therapy; use evidence to guide device sequencing

    The policy does not impose explicit step therapy or mandatory device sequencing; clinical evidence comparing prosthesis types may inform device selection for failure modes like peri‑prosthetic or endoprosthesis leakage.

    • No required trial of one prosthesis type before another is stated in the policy.
    • Evidence (e.g., Provox Vega vs XtraSeal, Provox Vega vs ActiValve) may guide selection for recurrent leakage or frequent replacements.
    Documentation Required

    Document removal/replacement technique (e.g., retrograde with Blom‑Singer TEP set)

    Providers should follow the documented guidance for removal and replacement techniques (e.g., retrograde removal with the Blom‑Singer TEP set) and include the method used in procedure notes.

    • If retrograde technique is used, document use of the Blom‑Singer TEP set and the steps taken to preserve the TEP tract.
    Documentation Required

    Recommendation by laryngologist or SLP and replacement rationale required

    A recommendation for initial insertion or replacement must come from a laryngologist or a speech‑language pathologist and the record must document the clinical rationale for replacement (e.g., leakage, device failure) consistent with the selection criteria.

    • Treatment plan should state that recommendation was made by a laryngologist or speech‑language pathologist.
    • Document the reason for replacement and note device lifespan expectation (typically 3–6 months when clinically indicated).
    Documentation Required

    Document procedure method and confirm eligibility at time of service

    Procedure documentation must state the removal/replacement method used and confirm the patient met the selection criteria (adequate pulmonary function and manual dexterity) at the time of service.

    • Include the specific technique (e.g., retrograde removal) and devices/tools used.
    • Confirm in the record that the member has adequate pulmonary function and manual dexterity per Appendix selection criteria.
    Note

    Reference policy history for administrative requirements

    Refer to the policy history for review dates and administrative changes; providers should consult the policy history for any updates that may affect coverage or preauthorization procedures.

    • Last review: 07/27/2023; Effective date: 08/17/2001; Next review: 06/13/2024.
    Documentation Required

    Document manual dexterity and pulmonary function — affects coverage

    Patient suitability factors such as manual dexterity and pulmonary function directly affect candidacy and therefore coverage; document these clinical assessments in the medical record.

    • Manual dexterity: ability to clean the prosthesis 2–3 times daily affects candidacy.
    • Pulmonary function: ability to force air through the prosthesis into the esophagus must be demonstrated.
    Denial Risk

    Not meeting selection criteria risks denial

    Failure to meet the policy’s selection criteria (inadequate pulmonary function or insufficient manual dexterity) may result in denial of coverage; ensure documentation supports suitability.

    • If records do not demonstrate the two Appendix selection criteria, prior authorization or claim payment may be denied.
    Note

    CPB notes: guidance only; not an offer of coverage

    Clinical Policy Bulletins are intended to assist in administering plan benefits and do not constitute offers of coverage; absence of coverage in a CPB does not change contract language—check member’s plan for definitive coverage terms.

    • CPBs provide a general description of benefits and are not a contract or guarantee of coverage.
    A tracheo-esophageal (TE) voice prosthesis designed to be inserted and removed by the patient (patient-inserted), e.g., Provox NiD.
    Clinical stanceConsidered medically necessary when recommended by a laryngologist or speech-language pathologist for voice rehabilitation following total laryngectomy.
    Device life commentStudies report favorable patient satisfaction and feasibility; device life can be comparable to indwelling devices in some cohorts (see device life literature).
    inv-26: Hand-held artificial larynx — definition and coverage stance
    DefinitionAn external electronic device used to generate voice for laryngectomized patients (examples: Nu Vois, OptiVox, Servox, SolaTone, TruTone, UltraVoice).
    Coverage stanceHand-held artificial larynx devices are considered medically necessary by the policy.
    Typical useProvides external alaryngeal speech generation for patients who have undergone total laryngectomy.
    inv-27: Ultrasonography for TEP sizing — use of ultrasound to guide prosthesis sizing
    Definition / purposeUse of ultrasonography (e.g., 16‑MHz measurement of the posterior tracheal wall) to determine tracheoesophageal wall thickness to guide prosthesis choice and sizing.
    Clinical utilityHelpful in patients with distorted or less predictable anatomy (e.g., flap reconstruction) and can change sizing decisions in a majority of patients in preliminary series.
    Evidence noteFindings are preliminary and authors state validation by well‑designed studies is needed.
    inv-28: Device variants — Provox Vega XtraSeal, Provox ActiValve and variant features
    Provox Vega XtraSealDouble‑flange (XtraSeal) design on the pharyngeal side intended to reduce peri‑prosthetic leakage and increase device lifespan compared with Provox Vega.
    Provox ActiValveMagnet‑based valve system designed for active valve closure to treat endoprosthetic leakage; substantially longer mean duration compared with Provox Vega but higher cost.
    Comparative findingsStudies report increased mean lifespan for XtraSeal and markedly longer duration for ActiValve (e.g., ActiValve median durations far exceed Vega in case‑crossover studies).
    Safety / considerationsImproper placement of XtraSeal may cause foreign body reaction, inflammation, extrusion, or pressure lesions; recommended measurement and placement protocols exist (e.g., Tower of Hercules protocol).